Modern scientific studies are often impeded by the limited availability of human biological materials such as tissue and DNA for conducting innovative research. Because of this critical need, it is the mission of Provia Biologics to increase the international availability of human biologics to aid worldwide diagnostic, prognostic and therapeutic studies. Access to many existing biologics banks is restricted. Additionally, the quality and consistent supply of material in these banks varies. It is also difficult for many reputable medical, academic, and biotech researchers to obtain the biologics necessary to conduct research that could conquer human disease.
The goal of Provia Biologics is to do well by doing good. The Provia group consists of respected scientists and organizations who are dedicated to obtaining, processing, and distributing human serum, protein extracts, DNA, and frozen, fixed, histologically processed tissue for use by the scientific community. Readily available processed and transformed biologics are in demand, and Provia Biologics is committed to applying the highest standards of ethics in obtaining and distributing biological samples for research.
Provia Biologics understands that in order for academic researchers, biotechnology and pharmaceutical companies to develop medical solutions for human disease, they must have access to relevant, high quality human biologics to discover new targets and test new markers. This translational research moves research from non-human cells and in vitro models into human models of in vitro evaluation and diagnostics, an efficacious approach that assists development of solutions in diseases like cancer, diabetes, hypertension, autoimmune diseases, and even aging.
This is a new paradigm to develop infrastructure for scientific research. Academic researchers, pharmaceutical and biotech companies representing the research intense health care systems in the developed nations have long been active in supporting public health and suppressing epidemic diseases in developing countries. Horizons are now expanding to include non-infectious diseases including cancer, atherosclerosis, and other diseases seen as life spans increase. In parallel, biotechnology has increased the pace of discovery such that supply of human biologics has become a huge block in moving health benefits from the laboratory to the populations in need. Advances in genetics, transplantation, basic cancer research, and drug discovery all require testing and validation in human subjects. Furthermore, these same advances in technology have opened opportunities for translational research that were simply not available previously. The new paradigm therefore recognizes not only the power of technology to produce discoveries at an increasing pace, but also that it is difficult for individual researchers or even groups of researchers in companies to access human biologics. There is increasing recognition that many populations and environments must be represented in validation studies for drugs and diagnostic tests. Provia has attracted the necessary scientific, medical, and biologics experts to provide critical needs to the scientific community.
